{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T10:23:03Z","timestamp":1790677383028,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.ymgme.2016.01.013","type":"journal-article","created":{"date-parts":[[2016,2,4]],"date-time":"2016-02-04T18:17:34Z","timestamp":1454609854000},"page":"413-418","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years"],"prefix":"10.1016","volume":"117","author":[{"given":"Karolina M.","family":"Stepien","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian J.","family":"Hendriksz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reena","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2016.01.013_bb0005","series-title":"The Metabolic and Molecular Bases of Inherited Disease","first-page":"3389","article-title":"Glycogen Storage Disease Type II: Acid Alpha-Glucosidase (Acid Maltase) Deficiency","author":"Hirschhorn","year":"2001"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0010","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","article-title":"Pompe's disease","volume":"372","author":"Van der Ploeg","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0015","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1750-1172-6-34","article-title":"Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy","volume":"6","author":"Gungor","year":"2011","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0020","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/brain\/awh384","article-title":"Clinical manifestation and natural course of late-onset Pompe's disease in 54 Dutch patients","volume":"128","author":"Hagemans","year":"2005","journal-title":"Brain"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0025","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00415-005-0922-9","article-title":"The natural course of non-classic Pompe's disease; a review of 225 published cases","volume":"252","author":"Winkel","year":"2005","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0030","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1056\/NEJMoa0909859","article-title":"A randomised study of alglucosidase alpha in late-onset Pompe's disease","volume":"362","author":"van der Ploeg","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0035","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ymgme.2008.09.001","article-title":"Improvement with ongoing enzyme replacement therapy in advanced late-onset Pompe disease: a case study","volume":"95","author":"Case","year":"2008","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0040","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1212\/01.wnl.0000313367.09469.13","article-title":"Filative arteriopathy and basilar artery dolichoectasia complicating late-onset Pompe disease","volume":"70","author":"Laforet","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0045","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1007\/s00415-010-5618-0","article-title":"Abnormalities of cerebral arteries are frequent in patients with late-onset Pompe disease","volume":"257","author":"Sacconi","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0050","article-title":"Intracerebral haemorrhage in a patient with glycogenosis type II: is there a pathophysiological relationship. letter to editor","volume":"2011","author":"Brettschneider","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0055","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1227\/00006123-198711000-00030","article-title":"Fusiform aneurism of basilar artery and ectatic internal carotid arteries associated with glycogenosis type 2 (Pompe disease)","volume":"21","author":"Braunsdorf","year":"1987","journal-title":"Neurosurgery"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0060","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0022-510X(90)90258-O","article-title":"Aneurysm and vacuolar degeneration of cerebral arteries in late onset acid maltase deficiency","volume":"98","author":"Kretzschmar","year":"1990","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0065","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.surneu.2007.05.049","article-title":"Thrombotic complications of a basilar artery aneurysm in a young adult with Pompe disease","volume":"70","author":"Refai","year":"2008","journal-title":"Surg. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ymgme.2011.02.004","article-title":"Pompe disease: design, methodology and early findings from the Pompe registry","volume":"103","author":"Byrne","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0075","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1750-1172-8-49","article-title":"Impact of enzyme replacement therapy on survival in adults with Pompe disease: results from a prospective international observational study","volume":"8","author":"Gungor","year":"2013","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0080","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10545-011-9393-6","article-title":"Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study","volume":"35","author":"Furusawa","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0085","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1007\/s10545-012-9451-8","article-title":"36months observational clinical study of 38 adult Pompe patients under alglucosidase alpha enzyme replacement therapy","volume":"35","author":"Regnery","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0090","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.nmd.2008.04.009","article-title":"Eight years experience with enzyme replacement therapy in two children and one adult with Pompe disease","volume":"18","author":"van Capelle","year":"2008","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0095","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1007\/s00415-011-6293-5","article-title":"Observational clinical study in juvenile\u2013adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4years","volume":"259","author":"Angelini","year":"2012","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0100","doi-asserted-by":"crossref","first-page":"e448","DOI":"10.1542\/peds.113.5.e448","article-title":"Long-term intravenous treatment of Pompe disease with recombinant human alpha-glucosidase from milk","volume":"113","author":"van der Hout","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0105","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nmd.2004.10.009","article-title":"Safety and efficacy of recombinant acid alpha-glucosidase (rhGAA) in patients with classical infantile Pompe disease: results of a phase II classical trial","volume":"15","author":"Klinge","year":"2005","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","article-title":"Recombinant human acid (alpha)- glucosidase: major clinical benefits in infantile-onset Pompe disease","volume":"68","author":"Kishnani","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0115","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00408-013-9489-x","article-title":"Enzyme replacement therapy improves respiratory outcomes in patients with late-onset type II glycogenosis and high ventilator dependency","volume":"191","author":"Vianello","year":"2013","journal-title":"Lung"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0120","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s00415-009-5275-3","article-title":"Enzyme replacement therapy with alpha glucosidase alpha in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial","volume":"257","author":"Strothotte","year":"2010","journal-title":"J. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0125","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1007\/s10545-010-9201-8","article-title":"Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II","volume":"33","author":"Bembi","year":"2010","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0130","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1164\/ajrccm.158.5.9710086","article-title":"Reference equations for the six-minute walk in healthy adults","volume":"158","author":"Enright","year":"1998","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0135","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jpeds.2006.12.052","article-title":"Six-minute walk test in children and adolescents","volume":"150","author":"Geiger","year":"2007","journal-title":"J. Pediatr."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0140","series-title":"User's Manual for the SF-36v2 Health Survey","author":"Ware","year":"2007"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0145","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ymgme.2011.06.012","article-title":"Rate of progression and predictive factors for pulmonary outcome in children and adults with Pompe disease","volume":"104","author":"van der Beek","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0150","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.nmd.2011.04.001","article-title":"Recombinant human acid alpha glucosidase (rhGAA) is adult patients with severe respiratory failure due to Pompe disease","volume":"21","author":"Orlikowski","year":"2011","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0155","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1183\/09031936.05.00020005","article-title":"Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease","volume":"26","author":"Pellegrini","year":"2005","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0160","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.nmd.2008.11.007","article-title":"Rate of disease progression during long-term follow-up of patients with late-onset Pompe disease","volume":"19","author":"der Beek","year":"2009","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0165","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1002\/mus.21025","article-title":"Clinical features of late-onset Pompe disease: a prospective cohort study","volume":"38","author":"Wokke","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0170","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.nmd.2007.06.002","article-title":"Late onset Pompe disease: clinical and neurophysiological spectrum of 38 patients including long-term follow-up in 18 patients","volume":"17","author":"M\u00fcller-Felber","year":"2007","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0175","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/1750-1172-7-73","article-title":"Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study","volume":"7","author":"de Vries","year":"2012","journal-title":"Orphanet. J. Rare. Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0180","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1212\/01.wnl.0000252798.25690.76","article-title":"Broad spectrum of Pompe disease in patients with the same c.-32-13T->G haplotype","volume":"9","author":"Kroos","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0185","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s13023-014-0102-z","article-title":"Genotype-phenotype correlation in Pompe disease, a step forward","volume":"9","author":"de Filippi","year":"2014","journal-title":"Orphanet. J. Rare.Dis."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0190","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/ajmg.c.31318","article-title":"The genotype-phenotype correlation in Pompe disease","volume":"160","author":"Kroos","year":"2012","journal-title":"Am. J. Med. Genet. C: Semin. Med. Genet."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0195","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1002\/mus.21933","article-title":"Molecular analysis and protein processing in late\u2013onset Pompe disease patients with low levels of acid alpha-glucosidase activity","volume":"43","author":"Bali","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0200","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1468-1331.2008.02377.x","article-title":"Glycogen storage disease type II (Pompe disease)\u2014influence of enzyme replacement therapy in adults","volume":"16","author":"Merk","year":"2009","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.ymgme.2016.01.013_bb0205","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1212\/01.WNL.0000158682.85052.C0","article-title":"Respiratory failure in Pompe disease: treatment with noninvasive ventilation","volume":"64","author":"Mellies","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2016.01.013_bb0210","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1007\/s10545-014-9728-1","article-title":"Effectiveness of enzyme replacement therapy in adults with late-onset Pompe disease: results from the NCS\u2013LSD cohort study","volume":"37","author":"Anderson","year":"2014","journal-title":"J. Inherit. Metab. Dis."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719216300129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,15]],"date-time":"2018-09-15T18:54:27Z","timestamp":1537037667000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719216300129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":42,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S1096719216300129"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.013","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2016.01.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}